Icecure Medical (ICCM) has released an update.
IceCure Medical reports a robust first quarter in 2024, with a 30% surge in sales of their ProSense® cryoablation system, reflecting growing global market adoption. The company has completed the landmark ICE3 trial for breast cancer, submitted comprehensive data to the FDA, and is awaiting a marketing clearance decision. Independent studies underscore ProSense®’s efficacy and safety, reinforcing its potential as a surgery-free treatment for breast cancer and other indications.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
